VivoSim Labs, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate
VivoSim Labs, Inc. (VIVS) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate of 112.08% for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate · last filed 2026-08-12
- VivoSim Labs, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2026-06-30 was 112.08%, a 5.58% decline year-over-year.
- VivoSim Labs, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2025-12-31 was 113.12%, a 12.19% increase year-over-year.
- VivoSim Labs, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2025-09-30 was 111.00%, a 12.12% increase year-over-year.
- VivoSim Labs, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2025-06-30 was 118.70%, a 16.73% increase year-over-year.
- VivoSim Labs, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2026 was 113.22%, a 13.93% increase from fiscal 2025.
- VivoSim Labs, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2025 was 99.38%, a 0.34% increase from fiscal 2024.
- VivoSim Labs, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2024 was 99.04%, a 3.67% increase from fiscal 2023.
- VivoSim Labs, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2023 was 95.53%, a 0.13% decline from fiscal 2022.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 1 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 1 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 6 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 12 month |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | 112.08% 10-Q · filed 2026-08-12 | ||||||
| 2026-03-31 | 113.22% 10-K · filed 2026-07-14 | ||||||
| 2025-12-31 | 113.12% 10-Q · filed 2026-02-11 | 112.72% 10-Q · filed 2026-02-11 | |||||
| 2025-09-30 | 111.00% 10-Q · filed 2025-11-06 | 112.30% 10-Q · filed 2025-11-06 | |||||
| 2025-06-30 | 118.70% 10-Q · filed 2026-08-12 | ||||||
| 2025-03-31 | 99.38% 10-K · filed 2026-07-14 | ||||||
| 2024-12-31 | 100.83% 10-Q · filed 2026-02-11 | 99.38% 10-Q · filed 2026-02-11 | |||||
| 2024-09-30 | 99.00% 10-Q · filed 2025-11-06 | 99.37% 10-Q · filed 2025-11-06 | |||||
| 2024-06-30 | 101.69% 10-Q · filed 2025-08-12 | ||||||
| 2024-03-31 | 99.04% 10-K · filed 2025-06-05 | ||||||
| 2023-12-31 | 100.31% 10-Q · filed 2025-02-19 | 98.93% 10-Q · filed 2025-02-19 | |||||
| 2023-09-30 | 0.00% 10-Q · filed 2024-11-08 | 98.51% 10-Q · filed 2024-11-08 | |||||
| 2023-06-30 | 98.51% 10-Q · filed 2024-08-05 | ||||||
| 2023-03-31 | 95.53% 10-K · filed 2024-05-31 | ||||||
| 2022-12-31 | 95.93% 10-Q · filed 2024-02-08 | 95.43% 10-Q · filed 2024-02-08 | |||||
| 2022-09-30 | 95.93% 10-Q · filed 2023-11-09 | 95.41% 10-Q · filed 2023-11-09 | |||||
| 2022-06-30 | 94.50% 10-Q · filed 2023-08-10 | ||||||
| 2022-03-31 | 95.65% 10-K · filed 2023-07-14 | ||||||
| 2021-12-31 | 95.42% 10-Q · filed 2023-02-09 | 95.96% 10-Q · filed 2023-02-09 | |||||
| 2021-09-30 | 116.83% 10-Q · filed 2022-11-10 | 116.83% 10-Q · filed 2022-11-10 | |||||
| 2021-06-30 | 0.00% 10-Q · filed 2022-08-11 | ||||||
| 2021-03-31 | 107.88% 10-K · filed 2022-06-10 | ||||||
| 2020-12-31 | 108.74% 10-Q · filed 2022-02-14 | 108.41% 10-Q · filed 2022-02-14 | |||||
| 2020-09-30 | 108.39% 10-Q · filed 2021-11-08 | 108.39% 10-Q · filed 2021-11-08 | |||||
| 2020-03-31 | 84.36% 10-K · filed 2021-06-15 | ||||||
| 2019-12-31 | 0.00% 10-Q · filed 2021-02-08 | 84.36% 10-Q · filed 2021-02-08 | |||||
| 2019-09-30 | 84.36% 10-Q · filed 2020-11-05 | 84.36% 10-Q · filed 2020-11-05 | |||||
| 2019-06-30 | 0.00% 10-Q · filed 2019-08-08 | ||||||
| 2019-03-31 | 72.99% 10-K · filed 2020-05-28 | ||||||
| 2018-12-31 | 73.07% 10-Q · filed 2020-02-10 | 72.99% 10-Q · filed 2020-02-10 | |||||
| 2018-09-30 | 73.19% 10-Q · filed 2019-11-07 | 72.98% 10-Q · filed 2019-11-07 | |||||
| 2018-06-30 | 72.25% 10-Q · filed 2019-08-08 | ||||||
| 2018-03-31 | 76.86% 10-K · filed 2019-06-03 | ||||||
| 2017-12-31 | 80.71% 10-Q · filed 2019-02-07 | 76.86% 10-Q · filed 2019-02-07 | |||||
| 2017-09-30 | 70.97% 10-Q · filed 2018-11-08 | 76.58% 10-Q · filed 2018-11-08 | 76.85% 10-Q · filed 2017-11-09 | ||||
| 2017-06-30 | 74.27% 10-Q · filed 2018-08-09 | ||||||
| 2017-03-31 | 72.17% 10-K · filed 2018-05-31 | ||||||
| 2016-12-31 | 72.99% 10-Q · filed 2018-02-08 | 72.08% 10-Q · filed 2018-02-08 | |||||
| 2016-09-30 | 72.28% 10-Q · filed 2017-11-09 | 72.04% 10-Q · filed 2017-11-09 | |||||
| 2016-06-30 | 71.30% 10-Q · filed 2017-08-09 | ||||||
| 2016-03-31 | 73.96% 10-K · filed 2018-05-31 | ||||||
| 2015-12-31 | 71.90% 10-Q · filed 2017-02-09 | 74.10% 10-Q · filed 2017-02-09 | |||||
| 2015-09-30 | 74.26% 10-Q · filed 2016-11-03 | 74.25% 10-Q · filed 2016-11-03 | |||||
| 2015-06-30 | 74.25% 10-Q · filed 2016-08-04 | ||||||
| 2015-03-31 | 76.90% 10-K · filed 2017-06-07 | ||||||
| 2014-12-31 | 77.00% 10-Q · filed 2016-02-08 | 77.10% 10-Q · filed 2016-02-08 | |||||
| 2014-11-30 | 73.40% 10-K · filed 2019-06-03 | 76.50% 10-Q · filed 2015-02-06 | |||||
| 2014-09-30 | 76.30% 10-Q · filed 2015-11-09 | 77.10% 10-Q · filed 2015-11-09 | |||||
| 2014-06-30 | 78.02% 10-Q · filed 2015-08-10 | ||||||
| 2014-03-31 | 78.22% 10-K · filed 2015-06-09 | ||||||
| 2013-12-31 | 82.30% 10-Q · filed 2015-02-06 | 83.90% 10-Q · filed 2015-02-06 | |||||
| 2013-11-30 | 96.90% 10-Q · filed 2014-11-07 | ||||||
| 2013-09-30 | 82.60% 10-Q · filed 2014-11-07 | 84.80% 10-Q · filed 2014-11-07 | 84.82% 10-Q · filed 2013-11-08 | ||||
| 2013-06-30 | 86.90% 10-Q · filed 2014-08-08 | ||||||
| 2013-03-31 | 96.83% 10-K · filed 2014-06-10 | ||||||
| 2012-12-31 | 96.20% 10-Q · filed 2014-02-06 | 90.80% 10-Q · filed 2014-02-06 | 96.22% 10-K · filed 2014-06-10 | ||||
| 2012-09-30 | 96.21% 10-Q · filed 2013-11-08 | 80.49% 10-Q · filed 2013-11-08 | 91.83% 10-Q · filed 2012-11-14 | ||||
| 2012-06-30 | 95.77% 10-Q · filed 2013-08-09 | 95.77% 10-Q · filed 2012-08-14 | |||||
| 2011-12-31 | 111.00% 10-KT · filed 2013-05-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| Calidi Biotherapeutics, Inc. (CLDI) | United States | $0.003B | |
| CURIS INC (CRIS) | United States | $0.002B | -0.05 |
| PharmaCyte Biotech, Inc. (PMCB) | United States | $0.005B | |
| Silexion Therapeutics Corp (SLXN) | $0.001B | ||
| AIM ImmunoTech Inc. (AIM) | United States | $0.006B | |
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |